Sees FY26 revenue $4.632B-$4.72B, consensus $4.66B. The company’s initial 2026 revenue guidance range of $4.632B-$4.72B, or reported growth of 7.6%-9.6% and 7.0%-9.0% on an organic basis, is supported by 8.6% – 10.6% reported and 8.0%-10.0% organic CAG Diagnostics recurring revenue growth. The guidance range for global CAG Diagnostics recurring revenue growth reflects expectations for sustained benefits from execution drivers, supporting continued solid volume gains, and an estimated 4% full-year benefit from net price improvement. 2026 EPS guidance of $14.29-$14.80 reflects expectations for solid organic revenue gains and a targeted 40-90 basis points of reported operating margin improvement.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- The Week That Was, The Week Ahead: Macro and Markets, Feb. 1
- IDXX Upcoming Earnings Report: What to Expect?
- IDEXX Laboratories: Seamless CEO Transition, Robust Innovation Pipeline, and Strong Execution Support Buy Rating
- Idexx CEO Jonathan Mazelsky to switch to chairman, Michael Erickson to succeed
- Idexx Laboratories announces planned CEO succession and transition